TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03645824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Patients receive up to 4 cycles of pacritinib before allo-SCT
Study: NCT04144686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Rehabilitation
Description: Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Rehabilitation
Description: Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
Study: NCT04214821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Solution
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Solution
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Solution
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Solution
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study: NCT02345447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal-based medication
Description: Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqueous ethanol solution non-distinguishable from verum
Study: NCT03628768

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study: NCT04377126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of saline- no active ingredient.
Study: NCT04599244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emergency pulpotomy
Description: removal of coronal pulp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emergency pulpotomy
Description: removal of coronal pulp
Study: NCT02599571

Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine content cigarettes
Description: Cigarettes containing a reduced amount of nicotine

Intervention type: OTHER
Group type: OTHER
Intervention: Very low nicotine content cigarettes
Description: Cigarettes containing a reduced amount of nicotine

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional nicotine content cigarettes
Description: Cigarettes containing a normal amount of nicotine

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional nicotine content cigarettes
Description: Cigarettes containing a normal amount of nicotine
Study: NCT03730649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane (broccoli sprout extract)
Description: Participants will topically apply Sulforaphane for a period of time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane (broccoli sprout extract)
Description: Participants will topically apply Sulforaphane for a period of time

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UV or visible light
Description: Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
Study: NCT02580539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Peptide-stimulated T cells 2 x 10\^7/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: Peptide-stimulated T cells per dose-escalation protocol
Study: NCT02464696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IPS cohort only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IPS cohort only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: Receive high flow oxygen therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Air Pressure Device
Description: Undergo NIPPV
Study: NCT03865979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viz RECRUIT
Description: Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
Study: NCT04334824

Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.

Intervention type: DRUG
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Description: Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
Study: NCT04876521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: low dose of Amisulpride at 100-300 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine-Fluoxetine Combination
Description: Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
Study: NCT03901755

Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product

Intervention type: DRUG
Intervention: Alprolix
Description: Extended half-life factor IX product
Study: NCT04318678

Intervention type: DRUG
Group type: OTHER
Intervention: CD123-CAR T
Description: To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
Study: NCT03845205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated AUD Treatment
Description: IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
Study: NCT03771716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African Dance
Description: Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: African Cultural Immersion
Description: The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
Study: NCT04017546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral capsule
Study: NCT04156087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/ML
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgical Microwave Ablation (MIS-MWA)
Description: Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
Study: NCT03951103

Intervention type: OTHER
Intervention: rFVIIIFc
Description: Drug according to prescription
Study: NCT04895891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS hand imaging
Description: For each patient, EOS images are compared with CT images
Study: NCT05033171

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EOS 2D/3D scanning
Description: EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
Study: NCT03418948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CC followed by EC
Description: CC = conventional colonoscopy EC = endocuff assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EC followed by CC
Description: CC = conventional colonoscopy EC = endocuff assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2x EC
Description: EC = endocuff assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2x CC
Description: CC = conventional colonoscopy
Study: NCT03448926

Intervention type: OTHER
Intervention: Treatment Recommendation Surveys
Description: Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.

Intervention type: DEVICE
Intervention: 7-gene biosignature
Description: Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
Study: NCT00651742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
Study: NCT04398433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-3107
Description: INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000
Description: CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
Study: NCT01074970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rucaparib
Description: Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
Study: NCT00509977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Treatment
Description: Light treatment applied to half of the face at each study visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Laser treatment applied to half of the face at each study visit
Study: NCT04265144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: 62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsies only for volunteers among patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar samples
Description: 50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
Study: NCT01873222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI & IVUS
Description: * Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided PCI & OFDI
Description: * Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up
Study: NCT02202005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Nevirapine 400mg PR tablet
Study: NCT04047602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Dose SRS
Description: Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
Study: NCT01648751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal estrogen
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Study: NCT02601612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D46cpΔM2-2 vaccine
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D46cpΔM2-2 vaccine
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered as nose drops
Study: NCT02852655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Study: NCT03361761

Intervention type: OTHER
Intervention: Health education program
Description: formalized/official Health education program

Intervention type: OTHER
Intervention: Health education program
Description: non formalized/official Health education program
Study: NCT03818854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Mesenchymal Stromal Cells
Description: Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Reconstitution Media
Description: 300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
Study: NCT03970746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC*lung01
Description: PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC*lung01
Description: PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC*lung01
Description: PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDC*lung01
Description: PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
Study: NCT02202005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 400mg PR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viramune®
Description: Viramune® 400 mg Retardtabletten
Study: NCT03970746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda Injectable Product
Description: The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda Injectable Product
Description: The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
Study: NCT02202005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viramune®
Description: Viramune® 400 mg Retardtabletten